Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 167Triple Negative Breast Neoplasms 14Neoplasm Metastasis 13Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Breast Neoplasms, Male 5Brain Neoplasms 4Prostatic Neoplasms 3Ovarian Neoplasms 3HER2-positive Advanced Breast Cancer 3Advanced Breast Cancer 3Small Cell Lung Carcinoma 2Sarcoma 2Pancreatic Neoplasms 2Lung Neoplasms 2HER2-negative Breast Cancer 2HER2 Positive Breast Cancer 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Recurrence 1Primary Breast Cancer 1Pheochromocytoma 1Patient Acceptance of Health Care 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraganglioma, Extra-Adrenal 1Metastatic HER2-positive Breast Cancer 1Meningeal Carcinomatosis 1Lymphoma, Non-Hodgkin 1Inflammatory Breast Neoplasms 1Hormone Receptor Positive Advanced Breast Cancer 1

Interventions

Docetaxel 4Epirubicin 3Cyclophosphamide 3Paclitaxel 2Vinorelbine 1Tamoxifen 1Iodine-123 1Fluorouracil 1Doxorubicin 1Carboplatin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Breast Cancer × Vinorelbine × Breast × Clear all
NCT03270007 2020-10-28

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Peking University

Phase 4 Unknown
304 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡